Cytoxan

Acute Coryza, Retinoblastoma, Lymphoma, Large B-Cell, Diffuse + 20 more

Treatment

41 FDA approvals

20 Active Studies for Cytoxan

What is Cytoxan

Cyclophosphamide

The Generic name of this drug

Treatment Summary

Cyclophosphamide is a medication that is used to treat certain types of cancer, such as lymphoma and leukemia. It is a precursor drug which needs to be activated in the liver in order to become effective and it has side effects such as alopecia (hair loss), sterility, birth defects, mutations, and cancer. It has also been used to defleec sheep.

Cyclophosphamide

is the brand name

image of different drug pills on a surface

Cytoxan Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cyclophosphamide

Cyclophosphamide

1959

75

Approved as Treatment by the FDA

Cyclophosphamide, otherwise called Cyclophosphamide, is approved by the FDA for 41 uses like Retinoblastoma and Lung Cancers .

Retinoblastoma

Lung Cancers

Glomerulonephritis

Non-Hodgkin's Lymphoma (NHL)

Adenocarcinoma of the Ovaries

Acute monocytic leukemia

histiocytic lymphoma

Hodgkins Disease (HD)

Acute Myeloid Leukemia (AML)

Breast Cancer

Multiple Myeloma (MM)

Disseminated Neuroblastoma

Nephrotic syndrome with lesion of minimal change glomerulonephritis

Chronic Myeloid Leukemia (CML)

Leukemia, Myelocytic, Acute

Burkitt Lymphoma (BL)

Lymphocytic Lymphomas

mixed-cell type lymphoma

Acute Lymphoblastic Leukemia (ALL)

Malignant Lymphomas

Chronic Lymphocytic Leukemia (CLL)

Hodgkin Disease

failure with corticosteroid therapy

Lung Cancer

Acute Myeloid Leukemia

Acute Coryza

Erythema Induratum

Neuroblastoma

Lymphoma, Non-Hodgkin

Acute Lymphoblastic Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Myeloid, Acute

Breast Cancer

Non-Hodgkin's Lymphoma

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Lymphoma, Non-Hodgkin

Adenocarcinoma

Multiple Myeloma

Lymphoma, Large B-Cell, Diffuse

Chronic Lymphocytic Leukemia

Retinoblastoma

Effectiveness

How Cytoxan Affects Patients

Cyclophosphamide is a cancer treatment drug that belongs to a group called alkylating agents. These drugs work by attaching small molecules called alkyl groups to certain parts of the DNA in cancer cells. This makes it hard for the cells to replicate, and eventually the cells die. Alkylating agents are not specific to any stage of the cell cycle and can also disrupt normal DNA function, causing cells to die.

How Cytoxan works in the body

Alkylating agents work by interfering with DNA and RNA. They attach alkyl groups to DNA bases, which damages the DNA and prevents it from being copied or transcribed. They also cause cross-links to form between atoms in the DNA, which also stops it from being copied or transcribed. Finally, they cause mispairing of the nucleotides which leads to mutations.

When to interrupt dosage

The prescribed dosage of Cytoxan depends on the diagnosed affliction, including Lymphoma, Glomerulonephritis and Leukemia, Myelocytic, Acute. The amount of dosage varies in line with the technique of delivery (e.g. Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular or Powder, for solution - Intravenous) referenced in the table beneath.

Condition

Dosage

Administration

Breast Cancer

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Leukemia, Lymphocytic, Chronic, B-Cell

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Hodgkin Disease

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Retinoblastoma

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Lymphoma, Large B-Cell, Diffuse

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Lymphoma, Non-Hodgkin

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Acute Myeloid Leukemia

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Acute Lymphoblastic Leukemia

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Lung Cancer

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

failure with corticosteroid therapy

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Lymphoma, Non-Hodgkin

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Chronic Lymphocytic Leukemia

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Multiple Sclerosis

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Erythema Induratum

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Glomerulonephritis

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Acute Coryza

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Lupus

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Leukemia, Myeloid, Acute

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Neuroblastoma

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Warnings

Cytoxan Contraindications

Condition

Risk Level

Notes

severely depressed bone marrow function

Do Not Combine

Urinary Bladder Neck Obstruction

Do Not Combine

There are 20 known major drug interactions with Cytoxan.

Common Cytoxan Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Cyclophosphamide.

Abetimus

Major

The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Abetimus.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Cyclophosphamide.

Cytoxan Toxicity & Overdose Risk

Common side effects of the drug include a decrease in white blood cells, high fever, hair loss, nausea, vomiting, and diarrhea.

image of a doctor in a lab doing drug, clinical research

Cytoxan Novel Uses: Which Conditions Have a Clinical Trial Featuring Cytoxan?

There are 1165 active clinical trials investigating the potential of Cytoxan to alleviate Breast Cancer, Lymphocytic Lymphomas and Multiple Myeloma.

Condition

Clinical Trials

Trial Phases

Acute Myeloid Leukemia

267 Actively Recruiting

Phase 2, Phase 3, Phase 1, Phase 4, Not Applicable, Early Phase 1

Multiple Sclerosis

127 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1

Non-Hodgkin's Lymphoma

115 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4

Hodgkin Disease

3 Actively Recruiting

Not Applicable, Phase 1

Multiple Myeloma

6 Actively Recruiting

Phase 1, Phase 2

Lung Cancer

168 Actively Recruiting

Phase 1, Not Applicable, Phase 3, Phase 2, Early Phase 1

Lymphoma, Large B-Cell, Diffuse

0 Actively Recruiting

Chronic Lymphocytic Leukemia

142 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4

Acute Lymphoblastic Leukemia

120 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4

Adenocarcinoma

2 Actively Recruiting

Phase 2, Phase 1

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

0 Actively Recruiting

Neuroblastoma

0 Actively Recruiting

Glomerulonephritis

1 Actively Recruiting

Phase 3

Leukemia, Myeloid, Acute

0 Actively Recruiting

Erythema Induratum

0 Actively Recruiting

failure with corticosteroid therapy

0 Actively Recruiting

Retinoblastoma

5 Actively Recruiting

Phase 2, Phase 1

Lymphoma, Non-Hodgkin

1 Actively Recruiting

Phase 1

Breast Cancer

21 Actively Recruiting

Phase 2, Phase 1, Not Applicable

Lupus

9 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1

Cytoxan Reviews: What are patients saying about Cytoxan?

5

Patient Review

1/24/2013

Cytoxan for Small Cell Cancer of the Lung

I was surprised that I never got sick while using this medication, especially since I expected to. It was really easy to take, which is great.

5

Patient Review

10/11/2011

Cytoxan for Breast Cancer

This treatment completely removed my overall body pain.

5

Patient Review

7/30/2010

Cytoxan for Scleroderma Lung Disease

I did not enjoy the experience.

5

Patient Review

8/8/2010

Cytoxan for Non-Hodgkin's Lymphoma

I was diagnosed with a rare condition called Vasculitis PAN Nodosa in October 2009, and have been taking the medication Cytoxan since. The dose was just increased to 100 mg., and will eventually be increased to 150 mg. I'm just starting to lose my hair, and am concerned about potential side effects.

4.3

Patient Review

3/30/2010

Cytoxan for Breast Cancer

4

Patient Review

3/26/2014

Cytoxan for Rheumatoid Arthritis

Cytoxan was prescribed to me after Prednisone failed to treat my Cryptogenic Organizing Pneumonia. I was very hesitant to try it because of the potential side-effects, but my doctor assured me that it was my best option. Thankfully, the Cytoxan worked and I'm now on the road to recovery.

3

Patient Review

7/29/2011

Cytoxan for Cancer of the Cervix

While this drug was effective in treating my father's kidney disease, it unfortunately also did a lot of damage to his lungs. I would urge caution to anyone considering this treatment.

3

Patient Review

9/2/2010

Cytoxan for Breast Cancer

I've been taking Cytoxan for a few months now, and it's helped shrink my tumor to the point where surgery and radiation are possible. The nausea and fatigue have been pretty tough to deal with, but it's worth it considering the results I've seen.

3

Patient Review

5/7/2010

Cytoxan for Breast Cancer

I was diagnosed with Triple Negative Breast Cancer October 2008. I had six chemo treatments -- Cytoxin and Taxotere. It seems to have worked. At this point I am cancer free. I did lose my hair, but it has grown back in just as full, and I have curls now, too, which I didn't have before. My nails aren't as strong as they used to be. They seem to peel easily now, but I'm alive so I'm counting my blessings!

2.7

Patient Review

4/23/2014

Cytoxan for Nephrotic Syndrome

I've been using this for approximately a year now and I believe that it's helped improve my symptoms.

2.7

Patient Review

10/12/2018

Cytoxan for Multiple Myeloma

I took this drug a week ago and now I can't stay awake. My arms and hands have lost control and I was admitted to the hospital for high calcium levels and confusion. I'm still weak all over and confused.

1.3

Patient Review

4/1/2010

Cytoxan for Scleroderma Lung Disease

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cytoxan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of chemo is Cytoxan?

"In some cases, health care professionals may use the trade name Cytoxan or Neosar when referring to the generic drug name cyclophosphamide. Cyclophosphamide is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug."

Answered by AI

What is Cytoxan used for?

"Cyclophosphamide is a chemotherapy drug used to treat various types of cancer by slowing or stopping cell growth, and also by decreasing the immune system's response to various diseases."

Answered by AI

What are long term side effects of Cytoxan?

"- Long-term side effects of the cancer drug cyclophosphamide include bladder damage and cancer, and bone marrow failure. Bladder cancer is a known risk, and can occur 10-15 years after the drug was given."

Answered by AI

Is Cytoxan the Red Devil?

"I have completed my last round of treatments involving the drugs Adriamycin and Cytoxan, which are often referred to by cancer patients as A/C. In the world of cancer treatment, Adriamycin is often called the “Red Devil,” both for its bright, red color and its nasty side effects."

Answered by AI

Clinical Trials for Cytoxan

Image of University of Illinois at Chicago in Chicago, United States.

Functional Balance Intervention for Multiple Sclerosis

40 - 90
All Sexes
Chicago, IL

The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of daily living among persons with multiple sclerosis (PwMS). Combined Specific Aims: Aim 1: Examine the effect of the FBI (Intervention Group) on physical function in PwMS compared to a stretching program (Control Group). Hypothesis 1: After four months of training, the FBI group will show significantly greater improvements in physical function compared to the stretching group. Aim 2: Examine the effect of the multicomponent FBI on cognitive function in PwMS compared to the stretching program. Hypothesis 2: After four months of training, the FBI group will show significantly greater improvements in cognitive function compared to the stretching group. Aim 3: Examine the effects of the multicomponent FBI compared to the Control Group among PwMS on measures of daily living (dual-task performance, balance confidence, community mobility, and quality of life). Hypothesis 3: After four months of training, the FBI group will show significantly greater improvements in measures of daily living compared to the stretching group. All assessment sessions will be conducted virtually via Zoom. All measures collected during the initial screening, pre-training assessment, training progression, and mid- and post-training assessment sessions will be administered either via Zoom with a Helper Buddy present or through survey links sent to participants via the UIC REDCap system. The training sessions will be performed independently by the participants in the presence of a Helper Buddy. The investigators will recruit 75 people with multiple sclerosis (PwMS) for this study. Eligible participants will be randomized to either the FBI (Intervention) or stretching (Control) group, followed by an onboarding session with a designated Helper Buddy. Training will occur twice weekly for four months. Based on the anticipated attrition rate, the investigators aim for 40 PwMS to complete the post-training assessments and finish the study.

Recruiting
Has No Placebo

University of Illinois at Chicago

Image of HealthPartners Frauenshuh Cancer Research Center in Saint Louis Park, United States.

Axelopran for Cancer

18+
All Sexes
Saint Louis Park, MN

The primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate. The primary study period for assessing the primary aim is through day 43 (6 weeks). The main questions it aims to answer are: * Does axelopran show a signal for efficacy in slowing tumor progression? * Is axelopran safe and tolerable for long-term use in this patient population? * Does axelopran show a signal for efficacy in improving bowel function and quality of life? * Does axelopran show a signal for efficacy in reducing systemic inflammation, cachexia, and prognostic serum biomarkers of inflammation? Patients will take axelopran as monotherapy after relapse or progression on or after standard systemic therapy. Clinician and patient must be willing to attempt a delay in next line of systemic cancer therapy (if available) until day 43 to assess change in cancer status on repeat imaging. Clinician can move to the next line of therapy whenever deemed clinically necessary. Participants will: * take oral axelopran capsules daily for up to 1 year, or longer if deriving benefit * attend 10 in-person study visits, each lasting approximately 1-2 hours * complete study procedures including but not limited to imaging exams, blood draws, electronic health surveys, and physical assessments

Phase 2
Waitlist Available

HealthPartners Frauenshuh Cancer Research Center (+1 Sites)

Dylan Zylla, MD, MS

Glycyx MOR Inc.

Image of National Institutes of Health Clinical Center in Bethesda, United States.

CD22 CAR T-cells for Acute Lymphoblastic Leukemia

3 - 65
All Sexes
Bethesda, MD

Background: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from a person and modifying them to better target cancer cells. CAR T-cell therapy that targets a marker called CD19 has been show to can cure ALL in many children and adults. But in about 50% of patients, the ALL comes back within a year. Researchers want to find out if a second treatment with CAR T-cell therapy that targets a different marker, CD22, can keep the cancer away longer. Objective: To see if CD22 CAR T-cell therapy can keep ALL away longer. Eligibility: People aged 3 to 65 years who have no signs of cancer after CD19 CAR T-cell treatment for ALL. Design: Participants will be screened. They will have imaging scans and tests of their heart function. A sample of tissue (biopsy) will be collected from their bone marrow. They will have a fluid sample collected from the area around their spinal cord. Participants will undergo collection of their white blood cells (T cells) during a procedure called leukapheresis. Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein. The cells will be altered in a lab to create CD22 CAR T-cell therapy. Participants will take drugs over 4 consecutive days to prepare their body for the CAR T-cell therapy; then they will receive their modified T cells through a tube inserted into a vein. Some people may need to stay in the hospital during treatment. Participants will have follow-up visits for 2 years.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Sara K Silbert, M.D.

Have you considered Cytoxan clinical trials?

We made a collection of clinical trials featuring Cytoxan, we think they might fit your search criteria.
Go to Trials
Image of University of California Davis Comprehensive Cancer Center in Sacramento, United States.

Olutasidenib + Azacitidine for Acute Myeloid Leukemia

18+
All Sexes
Sacramento, CA

This phase II trial studies how well giving olutasidenib with azacitidine, followed by olutasidenib maintenance, works in treating patients with IDH1-mutated acute myeloid leukemia (AML) who have received prior treatment with venetoclax plus a hypomethylating agent (HMA-Ven). Olutasidenib and azacitidine may inhibit the growth of cancer cells by blocking certain enzymes required for cell growth. Maintenance therapy can help prevent or delay cancer from coming back. Olutasidenib with azacitidine followed by olutasidenib maintenance may be effective in treating patients with IDH1-mutated AML who have received prior HMA-Ven.

Phase 2
Recruiting

University of California Davis Comprehensive Cancer Center

Brian Jonas, MD

Image of University of Nebraska Medical Center in Omaha, United States.

Exercise for Blood Cancer Survivors

18+
All Sexes
Omaha, NE

Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.

Phase 2
Waitlist Available

University of Nebraska Medical Center

Image of University of Rochester in Rochester, United States.

Facilitated Referral and Text Messaging for Lung Cancer

50 - 80
All Sexes
Rochester, NY

The objective of the proposed clinical trial is to determine if we can increase LCS among ED patients using a combination of facilitated referral to an LCS program plus text message reminders to get screened. Step 1 of the approach is to identify participants that are eligible for LCS. Step 2 is to randomize eligible study participants between two study arms: (1) basic referral for LCS (i.e. verbal referral with written materials), and (2) facilitated referral for LCS (i.e. submission of a requisition to LCS program by staff) plus a subsequent series of text messages aimed at generating intention and motivation to get screened. The investigators' preliminary work showed this approach was feasible in the ED setting. The proposed study will build on this preliminary work with the goal of having a significant positive impact on LCS uptake. A total of 300 individuals eligible for LCS will be recruited from a high-volume urban ED, randomized between study arms, and followed-up at 120 days to assess interval LCS uptake. The Specific Aims of the proposed project are, (1) Compare LCS uptake between the two study arms, (2) Identify predictors of individuals that are not up-to-date with LCS at the time of enrollment, and (3) Evaluate study participant feedback on (a) barriers and facilitators to getting screened and (b) acceptability and appropriateness of ED-based promotion of LCS. The study team is at the forefront of developing ED-based interventions to promote cancer screening. This project leverages the universal access setting of the ED to identify individuals at greatest risk for lung cancer and get them screened. A scalable ED-based intervention that increases LCS uptake would save lives.

Waitlist Available
Has No Placebo

University of Rochester

Have you considered Cytoxan clinical trials?

We made a collection of clinical trials featuring Cytoxan, we think they might fit your search criteria.
Go to Trials
Image of University of Utah in Salt Lake City, United States.

Emotional Awareness and Expression Therapy for Fibromyalgia in Lupus

18 - 65
All Sexes
Salt Lake City, UT

The goal of this clinical trial is to learn if a psychotherapy intervention works to relieve widespread pain in patients with lupus. The main questions it aims to answer are: Is the psychotherapy treatment safe for lupus patients? Are lupus patients able to complete the treatment? Can the treatment help improve chronic pain and other symptoms in lupus patients? Researchers will compare the treatment to a control (participants who will continue their medical treatment but will not receive psychotherapy for the time frame of the treatment) to see if the psychotherapy treatment works to relieve widespread pain and other lupus-related symptoms. Participants will: Fill out questionnaires before and after the treatment. Participate in 8 weekly treatment sessions, 2 hours per session, delivered via Zoom from their own home. Keep a list of medications and monitor any changes in their medication regimen.

Recruiting
Has No Placebo

University of Utah

Dan Kaufmann, PhD

Image of Washington University School of Medicine in St Louis, United States.

Supplemental Imaging for Breast Cancer

25 - 55
Female
St Louis, MO

Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Tabassum Ahmad, M.D.

Image of University of Virginia in Charlottesville, United States.

CD33 FPBMC for Acute Myelogenous Leukemia

18+
All Sexes
Charlottesville, VA

The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) where they still have detectable disease ("MRD+") after some treatment. Participants receive 4 weekly doses of CD33 FPBMC by intravenous infusion followed by 4-6 weeks of standard treatment with a hypomethylating agent (type of treatment such as decitabine or azacitidine) and possibly a drug called venetoclax. This is considered 1 cycle of study treatment and may be repeated up to 4 times during the study.

Phase 1
Recruiting

University of Virginia

Daniel Reed, MD

Image of National Institutes of Health Clinical Center in Bethesda, United States.

Baricitinib for Job Syndrome

12 - 120
All Sexes
Bethesda, MD

Background: Autosomal dominant hyper-IgE syndrome (HIES), also called Job syndrome, is a genetic disorder that affects the immune system. It can cause skin and lung infections and problems with blood vessels, connective tissues, and bones. People with HIES often have lupus-like disease or atopic dermatitis (skin rash). Researchers want to know if a drug approved to treat other immune system diseases (baricitinib) can help people with HIES. Objective: To test baricitinib in people with HIES with lupus-like disease or skin rash. Eligibility: People aged 12 years and older with HIES with lupus-like disease or skin rash. Design: Participants will have 5 clinic visits, 4 remote visits, and 2 phone visits in 9 months. Participants will be screened. They will have a physical exam with blood and urine tests. They will have tests of the speed and pressure of blood flow through their body: Blood pressure cuffs will be placed on each arm and leg; electrodes will be placed on the wrists and a microphone on the chest. The study has a 3-month lead-in period. Participants will not take the study drug during this time. They will continue with their usual medical care. They will have 2 phone calls with the study team. Baricitinib is a tablet taken by mouth. Participants will take 1 or 2 tablets by mouth every day for 6 months. They will start with a low dose and may increase to a higher dose. Blood and urine tests will be repeated during each study visit. Other tests may also be repeated during some visits. A skin sample may also be taken....

Phase 1
Recruiting

National Institutes of Health Clinical Center

Alexandra F Freeman, M.D.

Have you considered Cytoxan clinical trials?

We made a collection of clinical trials featuring Cytoxan, we think they might fit your search criteria.
Go to Trials